These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17682185)

  • 1. [Future direction of adjuvant chemotherapy for breast cancer following new risk categories of St. Gallen Consensus].
    Osaki A; Saeki T
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():407-13. PubMed ID: 17682185
    [No Abstract]   [Full Text] [Related]  

  • 2. [Advances in herceptin neoadjuvant therapy and adjuvant therapy of breast cancer].
    Wang LP; Shen KW; Shen ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):241-3. PubMed ID: 16875618
    [No Abstract]   [Full Text] [Related]  

  • 3. [Systemic pharmacotherapy in breast cancer].
    Boér K
    Orv Hetil; 2004 Jan; 145(4):187-92. PubMed ID: 14978885
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis and treatment of HER-2-positive breast cancer: Expert consensus of the Chinese Anti-Cancer Association].
    Jiang ZF; Shao ZM; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):158-60. PubMed ID: 20403251
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 and response to paclitaxel in node-positive breast cancer.
    Nash I
    N Engl J Med; 2008 Jan; 358(2):198; author reply 198-9. PubMed ID: 18193532
    [No Abstract]   [Full Text] [Related]  

  • 6. Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer.
    Mayer EL; Burstein HJ
    J Clin Oncol; 2008 Mar; 26(8):1198-200. PubMed ID: 18323544
    [No Abstract]   [Full Text] [Related]  

  • 7. Trastuzumab treatment in breast cancer.
    Montemurro F; Valabrega G; Aglietta M
    N Engl J Med; 2006 May; 354(20):2186; author reply 2186. PubMed ID: 16707759
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant chemotherapy for high-risk operable breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(13):1642-4. PubMed ID: 17404366
    [No Abstract]   [Full Text] [Related]  

  • 9. HER2 and response to paclitaxel in node-positive breast cancer.
    Roukos DH
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18193530
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 and response to paclitaxel in node-positive breast cancer.
    Ferretti G; Felici A; Cognetti F
    N Engl J Med; 2008 Jan; 358(2):197; author reply 198. PubMed ID: 18184969
    [No Abstract]   [Full Text] [Related]  

  • 11. Near-final word on adjuvant chemotherapy for breast cancer is good news.
    Vastag B
    J Natl Cancer Inst; 2005 Aug; 97(16):1178-9. PubMed ID: 16106020
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and efficacy of neo-adjuvant sequential dose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer.
    Sánchez-Muñoz A; García-Tapiador AM; Dueñas-García R; Jaén-Morago A; Ortega-Granados AL; Martínez-Ortega E; Fernández Morales M; Fernández-Navarro M; de la Torre Cabrera C; Dueñas B; Ureña C; Martínez J; Morales F; Ramírez-Tortosa C; Sánchez-Rovira P
    Breast J; 2008; 14(5):506-7. PubMed ID: 18705667
    [No Abstract]   [Full Text] [Related]  

  • 13. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in adjuvant therapy for breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2005 Sep; 3(9):688-90. PubMed ID: 16224442
    [No Abstract]   [Full Text] [Related]  

  • 16. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 17. Facilitating consensus by examining patterns of treatment effects.
    Gelber RD; Gelber S; ;
    Breast; 2009 Oct; 18 Suppl 3():S2-8. PubMed ID: 19914537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
    Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
    J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An interpretation of the EBCTCG data.
    Lewis JP
    Oncologist; 2007 May; 12(5):505-9. PubMed ID: 17522235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.